| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0099-9598(03)60001-5 |
| P698 | PubMed publication ID | 14593855 |
| P50 | author | Jaap Verweij | Q98683725 |
| Alex Sparreboom | Q71780219 | ||
| P2093 | author name string | Otto Soepenberg | |
| P2860 | cites work | Cancer Research | Q326097 |
| Drug Metabolism and Disposition | Q1261140 | ||
| Journal of Pharmacology and Experimental Therapeutics | Q1500272 | ||
| Haematologica | Q5638209 | ||
| Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas | Q77667993 | ||
| Phase II trial of topotecan for the treatment of mesothelioma | Q77695228 | ||
| More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin | Q77798696 | ||
| Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study | Q77854147 | ||
| Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma | Q78061392 | ||
| A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer | Q93896546 | ||
| Important advances in oncology | Q27711194 | ||
| Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA | Q27748892 | ||
| A model for the mechanism of human topoisomerase I | Q27748893 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study | Q28364196 | ||
| A phase I and pharmacokinetic study of intraperitoneal topotecan | Q28366214 | ||
| The domain organization of human topoisomerase I | Q28910330 | ||
| Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures | Q28910447 | ||
| Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry | Q30984313 | ||
| Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study | Q31431689 | ||
| High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma | Q32055895 | ||
| Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog | Q32073568 | ||
| Irinotecan in the treatment of colorectal cancer: clinical overview | Q32073589 | ||
| Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). | Q32092717 | ||
| Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors | Q33179163 | ||
| Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans | Q33179201 | ||
| Oral topoisomerase 1 inhibitors in adult patients: present and future | Q33180133 | ||
| Modulation of camptothecin analogs in the treatment of cancer: a review | Q33181805 | ||
| The use of oral cytotoxic and cytostatic drugs in cancer treatment | Q33183187 | ||
| Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity | Q33183439 | ||
| Modulation of irinotecan metabolism by ketoconazole | Q33183940 | ||
| Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan | Q33184156 | ||
| Effects of St. John's wort on irinotecan metabolism | Q33184162 | ||
| Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer | Q33328193 | ||
| Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. | Q33329060 | ||
| A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. | Q33329288 | ||
| Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics | Q33330597 | ||
| Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors | Q33330606 | ||
| Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group | Q33330623 | ||
| Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial | Q33330937 | ||
| Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients | Q33331346 | ||
| A phase II study of 9-aminocamptothecin in patients with refractory breast cancer | Q33331682 | ||
| Phase II trial of topotecan in malignant melanoma | Q73562813 | ||
| Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma | Q73585200 | ||
| Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics | Q73812598 | ||
| Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection | Q73814722 | ||
| Population pharmacokinetic model for topotecan derived from phase I clinical trials | Q73900863 | ||
| A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339) | Q73905129 | ||
| Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study | Q73916903 | ||
| A phase II study of topotecan administered five times daily in patients with advanced gastric cancer | Q73927027 | ||
| Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports | Q73948201 | ||
| Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin | Q74121312 | ||
| Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer | Q74222602 | ||
| Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks | Q74329812 | ||
| Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates | Q74469116 | ||
| Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer | Q74593436 | ||
| Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors | Q74611892 | ||
| Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration | Q74616350 | ||
| Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071) | Q74628254 | ||
| A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma | Q74635392 | ||
| A risk-benefit assessment of irinotecan in solid tumours | Q74692829 | ||
| Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice | Q74824090 | ||
| Secondary leukemias induced by topoisomerase-targeted drugs | Q77333785 | ||
| The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies | Q77395185 | ||
| Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide | Q77401717 | ||
| O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan | Q77417368 | ||
| Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors | Q77435869 | ||
| Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial | Q77665238 | ||
| International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents | Q40391405 | ||
| Topoisomerase inhibitors. A review of their therapeutic potential in cancer | Q40499871 | ||
| Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites | Q40530650 | ||
| Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer | Q40575774 | ||
| Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer | Q40606324 | ||
| Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. | Q40611414 | ||
| Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue | Q40648032 | ||
| Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy | Q40659621 | ||
| Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma | Q40669502 | ||
| Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer | Q40715776 | ||
| A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days | Q40731233 | ||
| Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan | Q40751042 | ||
| Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia | Q40804661 | ||
| Topoisomerase I inhibitors: topotecan and irenotecan | Q40807397 | ||
| Oral chemotherapy: rationale and future directions | Q40851033 | ||
| Clinical pharmacokinetics of irinotecan | Q40880283 | ||
| Patient preferences for oral versus intravenous palliative chemotherapy | Q40915962 | ||
| Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. | Q40916716 | ||
| Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f | Q40978962 | ||
| Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus | Q41119522 | ||
| The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. | Q41163991 | ||
| Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer | Q41188377 | ||
| The promoter region of the human type-I-DNA-topoisomerase gene. Protein-binding sites and sequences involved in transcriptional regulation | Q41517482 | ||
| Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line | Q41597979 | ||
| Topoisomerase I inhibitors: review and update | Q41634169 | ||
| Effects of CPT-11 in combination with other anti-cancer agents in culture | Q41639325 | ||
| Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity | Q41704097 | ||
| Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells | Q41752714 | ||
| The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid | Q43542620 | ||
| Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients | Q43693197 | ||
| Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin | Q43698387 | ||
| A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer | Q43740784 | ||
| Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer | Q43766558 | ||
| A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer | Q43828848 | ||
| A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma | Q43836493 | ||
| Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer | Q43850218 | ||
| Phase I clinical and pharmacologic trial of intravenous estramustine phosphate | Q43886340 | ||
| Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma | Q43922127 | ||
| Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer | Q44015246 | ||
| Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. | Q44044782 | ||
| Urinary and fecal excretion of topotecan in patients with malignant solid tumours | Q44058880 | ||
| Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis | Q44083716 | ||
| Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin | Q44088576 | ||
| Osteosarcomas and adult soft tissue sarcomas: Is there a place for high LET radiation therapy? | Q44182595 | ||
| Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia | Q44461372 | ||
| Phase I and pharmacokinetic study of intraperitoneal topotecan | Q46043090 | ||
| Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin | Q47842166 | ||
| Irinotecan therapy in adults with recurrent or progressive malignant glioma | Q48207492 | ||
| Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. | Q50950480 | ||
| Mutagenic properties of topoisomerase-targeted drugs. | Q52531966 | ||
| Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. | Q53715458 | ||
| The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. | Q53963181 | ||
| Clinical, pharmacokinetic and biological studies of topotecan. | Q54036451 | ||
| A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. | Q54041945 | ||
| Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. | Q54049254 | ||
| A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. | Q54167076 | ||
| Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro | Q54255888 | ||
| Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. | Q54982736 | ||
| Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. | Q55196356 | ||
| Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 | Q56864507 | ||
| Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan | Q59358959 | ||
| Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer | Q61868290 | ||
| Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice | Q67486552 | ||
| Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer | Q33503990 | ||
| Topotecan. A review of its potential in advanced ovarian cancer | Q33504167 | ||
| A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion | Q33504409 | ||
| A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer | Q33504516 | ||
| Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. | Q33677099 | ||
| Enhanced somatic mutation rates induced in stem cells of mice by low chronic exposure to ethylnitrosourea | Q33702163 | ||
| The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome | Q34057969 | ||
| Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy | Q34288389 | ||
| Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. | Q34336896 | ||
| Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. | Q34366002 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. | Q34754672 | ||
| Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer | Q35977364 | ||
| Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor | Q36135270 | ||
| Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer | Q36431552 | ||
| Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development | Q36431807 | ||
| Oral topotecan: bioavailablity and effect of food co-administration | Q36620382 | ||
| Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma | Q36621705 | ||
| Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study | Q36836814 | ||
| Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro | Q36895601 | ||
| Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours | Q36899705 | ||
| Topoisomerase-specific drug sensitivity in relation to cell cycle progression | Q36920787 | ||
| Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice | Q37352745 | ||
| Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | Q37378223 | ||
| Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death | Q37601249 | ||
| Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. | Q38310198 | ||
| A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay | Q38318734 | ||
| A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer | Q33331774 | ||
| Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study | Q33331940 | ||
| Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). | Q33332083 | ||
| DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies | Q33333842 | ||
| Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study | Q33334181 | ||
| Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma | Q33339001 | ||
| A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients | Q33339212 | ||
| Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer | Q33341045 | ||
| Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer | Q33341120 | ||
| Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study | Q33342696 | ||
| Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme | Q33343042 | ||
| Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors | Q33343374 | ||
| Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer | Q33343743 | ||
| Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer | Q33344308 | ||
| Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor | Q33350574 | ||
| Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer | Q33487960 | ||
| Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion | Q33488685 | ||
| Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor | Q33489257 | ||
| Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen | Q33492322 | ||
| Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration | Q33495553 | ||
| Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy | Q33495774 | ||
| Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure | Q33495882 | ||
| Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group | Q33496743 | ||
| A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer | Q33498400 | ||
| Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer | Q33498653 | ||
| Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors | Q33498657 | ||
| The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor | Q33500497 | ||
| 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. | Q33500679 | ||
| Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study | Q33500972 | ||
| Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study | Q33501662 | ||
| Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). | Q33502171 | ||
| Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas | Q33503047 | ||
| Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study | Q33503056 | ||
| Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer | Q33503969 | ||
| CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer | Q67504713 | ||
| Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer | Q68252500 | ||
| DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts | Q69360455 | ||
| Localization of the active type I DNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23-24 and 22q11.2-13.1. | Q69362155 | ||
| DNA topoisomerases | Q70095180 | ||
| Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins | Q70616408 | ||
| Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group | Q70970931 | ||
| Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function | Q71093671 | ||
| Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients | Q71121113 | ||
| Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial | Q71261842 | ||
| Phase II study of topotecan in metastatic hormone-refractory prostate cancer | Q71321842 | ||
| Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer | Q71572036 | ||
| Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas | Q71574198 | ||
| A phase II trial of topotecan in patients with previously untreated pancreatic cancer | Q71579235 | ||
| Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer | Q71604258 | ||
| Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer | Q71692731 | ||
| Phase I and pharmacologic study of topotecan in patients with impaired renal function | Q71861177 | ||
| Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer | Q71975354 | ||
| Phase I study of CPT-11 and etoposide in patients with refractory solid tumors | Q72098386 | ||
| Clinical studies of irinotecan alone and in combination with cisplatin | Q72149455 | ||
| Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts | Q72252535 | ||
| Phase II study of topotecan in metastatic non-small-cell lung cancer | Q72256259 | ||
| Topoisomerase I inhibition: a new target or new missiles? | Q72327065 | ||
| Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks | Q72368989 | ||
| Phase I and pharmacokinetic trial of weekly CPT-11 | Q72576855 | ||
| Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor | Q72609210 | ||
| Enzymes that push DNA around | Q73037272 | ||
| Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells | Q73044019 | ||
| Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan | Q73088375 | ||
| Effects of extended chronic exposures on endogenous and transgenic loci: implications for low-dose extrapolations | Q73102506 | ||
| Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors | Q73181530 | ||
| Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients | Q73356010 | ||
| Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and | Q73368715 | ||
| A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent | Q73376814 | ||
| Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408 | Q73392354 | ||
| Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer | Q73443071 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-50 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | The alkaloids. Chemistry and biology | Q26842446 |
| P1476 | title | Clinical studies of camptothecin and derivatives | |
| P478 | volume | 60 |
| Q45220663 | Molecular characterization of two anthranilate synthase alpha subunit genes in Camptotheca acuminata | cites work | P2860 |
Search more.